Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
AstraZeneca
Boehringer Ingelheim
Express Scripts
Mallinckrodt

Last Updated: May 28, 2022

Investigational Drug Information for DEBIO-1347


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for DEBIO-1347?

DEBIO-1347 is an investigational drug.

There have been 24 clinical trials for DEBIO-1347. The most recent clinical trial was a Phase 2 trial, which was initiated on August 7th 2020.

The most common disease conditions in clinical trials are Bacterial Infections, Lymphoma, and Hepatitis, Chronic. The leading clinical trial sponsors are Debiopharm International SA, Merck Sharp & Dohme Corp., and Centre Leon Berard.

There are five US patents protecting this investigational drug and eighty-two international patents.

Recent Clinical Trials for DEBIO-1347
TitleSponsorPhase
A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)Debiopharm International SAPhase 1
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid TumorsDebiopharm International SAPhase 1
A Study of Debio 1143 (Xevinapant) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for DefinitivGORTEC (Head and Neck Oncology and Radiotherapy Group)Phase 3

See all DEBIO-1347 clinical trials

Clinical Trial Summary for DEBIO-1347

Top disease conditions for DEBIO-1347
Top clinical trial sponsors for DEBIO-1347

See all DEBIO-1347 clinical trials

US Patents for DEBIO-1347

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
DEBIO-1347 See Plans and Pricing FGFR gatekeeper mutant gene and drug targeting same Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) See Plans and Pricing
DEBIO-1347 See Plans and Pricing FGFR3 fusion gene and pharmaceutical drug targeting same Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) See Plans and Pricing
DEBIO-1347 See Plans and Pricing Aminopyrazole derivative Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) F. Hoffmann-La Roche AG (Basel, CH) See Plans and Pricing
DEBIO-1347 See Plans and Pricing Aminopyrazole derivative Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) F. Hoffmann-La Roche AG (Basel, CH) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for DEBIO-1347

Drugname Country Document Number Estimated Expiration Related US Patent
DEBIO-1347 Denmark DK3087986 2033-12-27 See Plans and Pricing
DEBIO-1347 European Patent Office EP3087986 2033-12-27 See Plans and Pricing
DEBIO-1347 European Patent Office EP3581179 2033-12-27 See Plans and Pricing
DEBIO-1347 Spain ES2756175 2033-12-27 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
AstraZeneca
Boehringer Ingelheim
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.